{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:47:57Z","timestamp":1780116477688,"version":"3.54.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T00:00:00Z","timestamp":1283212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s12185-010-0674-x","type":"journal-article","created":{"date-parts":[[2010,8,30]],"date-time":"2010-08-30T00:46:40Z","timestamp":1283129200000},"page":"246-254","source":"Crossref","is-referenced-by-count":31,"title":["Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?"],"prefix":"10.1007","volume":"92","author":[{"given":"Ph.","family":"Solal-C\u00e9ligny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Cahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,31]]},"reference":[{"key":"674_CR1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","volume":"23","author":"WT Swenson","year":"2005","unstructured":"Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019\u201326.","journal-title":"J Clin Oncol"},{"key":"674_CR2","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","volume":"24","author":"Q Liu","year":"2006","unstructured":"Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25\u00a0years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582\u20139.","journal-title":"J Clin Oncol"},{"key":"674_CR3","doi-asserted-by":"crossref","unstructured":"National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112\u201335.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"674_CR4","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.1999.17.8.2499","volume":"17","author":"D Decaudin","year":"1999","unstructured":"Decaudin D, Lepage E, Brousse N, Brice P, Harousseau JL, Belhadj K, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients\u2014a study of the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1999;17:2499\u2013505.","journal-title":"J Clin Oncol"},{"key":"674_CR5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15:1110\u20137.","journal-title":"J Clin Oncol"},{"key":"674_CR6","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987\u201394.","DOI":"10.1056\/NEJM199309303291402"},{"key":"674_CR7","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1994.12.7.1343","volume":"12","author":"A Lopez-Guillermo","year":"1994","unstructured":"Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for Aggressive Lymphomas to patients with low-grade lymphoma. J Clin Oncol. 1994;12:1343\u20138.","journal-title":"J Clin Oncol"},{"key":"674_CR8","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.1994.12.7.1340","volume":"12","author":"Y Bastion","year":"1994","unstructured":"Bastion Y, Coiffier B. Is the International Prognostic Index for Aggressive Lymphoma patients useful for follicular lymphoma patients? J Clin Oncol. 1994;12:1340\u20132.","journal-title":"J Clin Oncol"},{"key":"674_CR9","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdi269","volume":"16","author":"G Perea","year":"2005","unstructured":"Perea G, Altes A, Montoto S, Lopez-Guillermo A, Domingo-Domenech E, Fernandez-Sevilla A, et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol. 2005;16:1508\u201313.","journal-title":"Ann Oncol"},{"key":"674_CR10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/10428190701237911","volume":"48","author":"P Solal-Celigny","year":"2007","unstructured":"Solal-Celigny P. What is the optimal prognostic tool for the assessment of patients with newly diagnosed follicular lymphoma? Leuk Lymphoma. 2007;48:452\u20133.","journal-title":"Leuk Lymphoma"},{"key":"674_CR11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"674_CR12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000253026","volume":"122","author":"V Formica","year":"2009","unstructured":"Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients. Acta Haematol. 2009;122:193\u20139.","journal-title":"Acta Haematol"},{"key":"674_CR13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.leukres.2005.07.006","volume":"30","author":"L Arcaini","year":"2006","unstructured":"Arcaini L, Colombo N, Passamonti F, Burcheri S, Orlandi E, Brusamolino E, et al. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leuk Res. 2006;30:277\u201382.","journal-title":"Leuk Res"},{"key":"674_CR14","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504\u20138.","journal-title":"Blood"},{"key":"674_CR15","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579\u201386.","journal-title":"J Clin Oncol"},{"key":"674_CR16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"674_CR17","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"674_CR18","doi-asserted-by":"crossref","unstructured":"Arcaini L, Merli M, Passamonti F, Rizzi S, Ferretti V, Rattotti S, et al. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol. 2010;149(3):455\u20137.","DOI":"10.1111\/j.1365-2141.2009.08065.x"},{"key":"674_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.beha.2004.08.019","volume":"18","author":"R Buckstein","year":"2005","unstructured":"Buckstein R, Pennell N, Berinstein NL. What is remission in follicular lymphoma and what is its relevance? Best Pract Res Clin Haematol. 2005;18:27\u201356.","journal-title":"Best Pract Res Clin Haematol"},{"key":"674_CR20","doi-asserted-by":"crossref","unstructured":"Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival\u2014a study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2010;28:822\u20139.","DOI":"10.1200\/JCO.2009.22.7819"},{"key":"674_CR21","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725\u201332.","journal-title":"Blood"},{"key":"674_CR22","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986\u201392.","journal-title":"J Clin Oncol"},{"key":"674_CR23","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","volume":"22","author":"MS Czuczman","year":"2004","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711\u20136.","journal-title":"J Clin Oncol"},{"key":"674_CR24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"674_CR25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CLM.2008.n.040","volume":"8","author":"A Janikova","year":"2008","unstructured":"Janikova A, Bolcak K, Pavlik T, Mayer J, Kral Z. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma. 2008;8:287\u201393.","journal-title":"Clin Lymphoma Myeloma"},{"key":"674_CR26","doi-asserted-by":"crossref","unstructured":"van Oers MH, Tonnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, et al. BCL-2\/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed\/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol. 2010;28:2246\u201352.","DOI":"10.1200\/JCO.2009.25.0852"},{"key":"674_CR27","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1182\/blood.V99.12.4265","volume":"99","author":"JJ Biagi","year":"2002","unstructured":"Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood. 2002;99:4265\u201375.","journal-title":"Blood"},{"key":"674_CR28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2008-07-168682","volume":"113","author":"T Katzenberger","year":"2009","unstructured":"Katzenberger T, Kalla J, Leich E, Stocklein H, Hartmann E, Barnickel S, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009;113:1053\u201361.","journal-title":"Blood"},{"key":"674_CR29","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2004-06-2490","volume":"105","author":"A Rambaldi","year":"2005","unstructured":"Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, et al. Quantitative PCR of bone marrow BCL2\/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood. 2005;105:3428\u201333.","journal-title":"Blood"},{"key":"674_CR30","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood.V84.4.1043.1043","volume":"84","author":"H Tilly","year":"1994","unstructured":"Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A, Monconduit M, et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood. 1994;84:1043\u20139.","journal-title":"Blood"},{"key":"674_CR31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/gcc.10314","volume":"39","author":"M Hoglund","year":"2004","unstructured":"Hoglund M, Sehn L, Connors JM, Gascoyne RD, Siebert R, Sall T, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer. 2004;39:195\u2013204.","journal-title":"Genes Chromosomes Cancer"},{"key":"674_CR32","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159\u201369.","journal-title":"N Engl J Med"},{"key":"674_CR33","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1182\/blood-2007-10-115915","volume":"111","author":"RJ Byers","year":"2008","unstructured":"Byers RJ, Sakhinia E, Joseph P, Glennie C, Hoyland JA, Menasce LP, et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood. 2008;111:4764\u201370.","journal-title":"Blood"},{"key":"674_CR34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","volume":"25","author":"AM Glas","year":"2007","unstructured":"Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25:390\u20138.","journal-title":"J Clin Oncol"},{"key":"674_CR35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1078-0432.CCR-06-1734","volume":"13","author":"BE Wahlin","year":"2007","unstructured":"Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res. 2007;13:388\u201397.","journal-title":"Clin Cancer Res"},{"key":"674_CR36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","volume":"26","author":"D Canioni","year":"2008","unstructured":"Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008;26:440\u20136.","journal-title":"J Clin Oncol"},{"key":"674_CR37","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","volume":"106","author":"P Farinha","year":"2005","unstructured":"Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106:2169\u201374.","journal-title":"Blood"},{"key":"674_CR38","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","volume":"24","author":"AM Lee","year":"2006","unstructured":"Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. 2006;24:5052\u20139.","journal-title":"J Clin Oncol"},{"key":"674_CR39","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","volume":"13","author":"M Taskinen","year":"2007","unstructured":"Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13:5784\u20139.","journal-title":"Clin Cancer Res"},{"key":"674_CR40","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood.V75.5.1154.1154","volume":"75","author":"MC Jacob","year":"1990","unstructured":"Jacob MC, Piccinni MP, Bonnefoix T, Sotto MF, Couderc P, Bensa JC, et al. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin\u2019s lymphoma: reactivity toward the malignant clone. Blood. 1990;75:1154\u201362.","journal-title":"Blood"},{"key":"674_CR41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1021696902187","volume":"8","author":"C Dallman","year":"2003","unstructured":"Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD40. Apoptosis. 2003;8:45\u201353.","journal-title":"Apoptosis"},{"key":"674_CR42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2009.07651.x","volume":"145","author":"A Carbone","year":"2009","unstructured":"Carbone A, Gloghini A, Cabras A, Elia G. The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol. 2009;145:468\u201380.","journal-title":"Br J Haematol"},{"key":"674_CR43","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","volume":"16","author":"BE Wahlin","year":"2009","unstructured":"Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2014positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2009;16:637\u201350.","journal-title":"Clin Cancer Res"},{"key":"674_CR44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.23881","volume":"124","author":"WZ Ai","year":"2009","unstructured":"Ai WZ, Hou JZ, Zeiser R, Czerwinski D, Negrin RS, Levy R. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer. 2009;124:239\u201344.","journal-title":"Int J Cancer"},{"key":"674_CR45","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-09-0266","volume":"69","author":"ZZ Yang","year":"2009","unstructured":"Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin\u2019s lymphoma. Cancer Res. 2009;69:5522\u201330.","journal-title":"Cancer Res"},{"key":"674_CR46","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1172\/JCI200423395","volume":"114","author":"Z Fehervari","year":"2004","unstructured":"Fehervari Z, Sakaguchi S. CD4+ T-regs and immune control. J Clin Invest. 2004;114:1209\u201317.","journal-title":"J Clin Invest"},{"key":"674_CR47","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"UK Liyanage","year":"2002","unstructured":"Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756\u201361.","journal-title":"J Immunol"},{"key":"674_CR48","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","volume":"108","author":"J Carreras","year":"2006","unstructured":"Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957\u201364.","journal-title":"Blood"},{"key":"674_CR49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","volume":"115","author":"P Farinha","year":"2010","unstructured":"Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115:289\u201395.","journal-title":"Blood"},{"key":"674_CR50","doi-asserted-by":"crossref","unstructured":"Sweetenham JW, Goldman B, Leblanc ML, Cook JR, Tubbs RR, Press OW, et al. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol. 2010;21(6):1196\u2013202.","DOI":"10.1093\/annonc\/mdp460"},{"key":"674_CR51","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1172\/JCI200422325","volume":"114","author":"HW Lim","year":"2004","unstructured":"Lim HW, Hillsamer P, Kim CH. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest. 2004;114:1640\u20139.","journal-title":"J Clin Invest"},{"key":"674_CR52","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"674_CR53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","volume":"19","author":"ME Keir","year":"2007","unstructured":"Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19:309\u201314.","journal-title":"Curr Opin Immunol"},{"key":"674_CR54","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","volume":"27","author":"J Carreras","year":"2009","unstructured":"Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009;27:1470\u20136.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0674-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-010-0674-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0674-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T01:45:33Z","timestamp":1591839933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-010-0674-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,31]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s12185-010-0674-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,31]]}}}